Guidelines on the management of AL amyloidosis
Authors:
- Helen J. LachmannHLHelen J. Lachmann
- the BCSH CommitteeTCthe BCSH Committee
- 10 October 2014
- journal article
- practice guideline
- Published by Wiley in British Journal of Haematology
- Vol. 168 (2) , 186-206
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialBlood, 2012
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisBlood, 2012
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementBlood, 2012
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresBlood, 2010
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- Appraisal of immunoglobulin free light chain as a marker of responseBlood, 2008
- Review article: gastrointestinal amyloidosis – clinical features, diagnosis and therapyAlimentary Pharmacology & Therapeutics, 2008
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65Blood, 2006
- An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisBone Marrow Transplantation, 2001